Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study. | Jpn J Clin Oncol | 2026 | 41887616 | PubTator, text mining | PubMed |
| Antibody-drug conjugates in prostate cancer: current landscape and future directions. | Ther Adv Med Oncol | 2026 | 41883865 | PubTator, text mining | PubMed |
| Advanced imaging techniques for tumor intraoperative navigation imaging. | Npj Imaging | 2026 | 41882234 | PubTator, text mining | PubMed |
| Silencing RPL9 promotes malignant proliferation in breast cancer cells. | Int J Immunopathol Pharmacol | 2026 | 41877589 | PubTator, text mining | PubMed |
| Cellular landscape and diagnostic value of TROP2 in cerebrospinal fluid of lung adenocarcinoma leptomeningeal metastases. | NPJ Precis Oncol | 2026 | 41876785 | PubTator, text mining | PubMed |
| [Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)]. | Zhonghua Zhong Liu Za Zhi | 2026 | 41876196 | PubTator, text mining | PubMed |
| Recent Advances in Targeted Therapies for Adult Gliomas. | Curr Neurol Neurosci Rep | 2026 | 41874881 | PubTator, text mining | PubMed |
| Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial. | J Thorac Oncol | 2026 | 41871716 | PubTator, text mining | PubMed |
| CX3CL1-CX3CR1 signaling orchestrates malignant progression of prostate cancer through luminal progenitor-macrophage crosstalk. | Cell Oncol (Dordr) | 2026 | 41870750 | PubTator, text mining | PubMed |
| Exploring Trop-2-Nanobody PPI Interactions through Molecular Dynamics Simulations and Biovalidations. | ACS Omega | 2026 | 41867620 | PubTator, text mining | PubMed |
| Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies. | Drug Deliv | 2026 | 41866709 | PubTator, text mining | PubMed |
| [Summary of second-line treatment of stage IV NSCLC without oncogenic addiction]. | Bull Cancer | 2026 | 41862326 | PubTator, text mining | PubMed |
| Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. | ESMO Open | 2026 | 41861751 | PubTator, text mining | PubMed |
| The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents. | Curr Opin Urol | 2026 | 41861349 | PubTator, text mining | PubMed |
| Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review. | Breast Cancer (Dove Med Press) | 2026 | 41858526 | PubTator, text mining | PubMed |
| A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. | Cell Rep Med | 2026 | 41856115 | PubTator, text mining | PubMed |
| Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. | Cell Rep Med | 2026 | 41850242 | PubTator, text mining | PubMed |
| Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities. | Genome Med | 2026 | 41845530 | PubTator, text mining | PubMed |
| Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma. | J Pathol Clin Res | 2026 | 41837391 | PubTator, text mining | PubMed |
| Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer. | NPJ Precis Oncol | 2026 | 41826432 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=12